ZYGEL
DEAD

Serial Number

98130731

Owner

Zynerba Pharmaceuticals, Inc.

Attorney

Sarah Anne Keefe

Filing Date

Aug 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ZYGEL Trademark

Serial Number: 98130731

ZYGEL is a trademark filed by Zynerba Pharmaceuticals, Inc. on August 14, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Zynerba Pharmaceuticals, Inc. (9 trademarks)

Suite 300
Devon, PA 19333

Entity Type: 03

Trademark Details

Filing Date

August 14, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders and all of the foregoing solely derived from manufactured synthetic cannabidiol and which do not contain delta-9 tetrahydrocannabinol (THC)

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 25, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 25, 2026 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 30, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 30, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 7, 2025 GNRN
NON-FINAL ACTION E-MAILED
Oct 7, 2025 GNRT
NON-FINAL ACTION WRITTEN
Oct 7, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 5, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 2, 2023 DOCK
ASSIGNED TO EXAMINER
Sep 27, 2023 DOCK
ASSIGNED TO EXAMINER
Sep 20, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 14, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 13, 2023 NWOS
NEW APPLICATION ENTERED
Aug 17, 2023 NWAP